The discrepancy between the findings of the study conducted by Lamar et al. and our study might be attributable in part to the inclusion in the study by Lamar et al. of patients treated with DA-EPOCH-R, a regimen that entails higher steroid doses than those used in R-CHOP, as well as the putatively lower incidence of hyperglycemia in the cohort examined in our study (vide supra). This evidence concerns the gene DDIT3 and Hyperglycemia.